Votiva it’s an FDA-cleared, non-surgical radiofrequency (RF) device/system (from InMode) used for vaginal rejuvenation and pelvic floor restoration.

Key Uses of Votiva

It primarily addresses:

• Stress urinary incontinence (SUI) – leakage with coughing, sneezing, exercise, etc.
• Vaginal laxity/tissue laxity after childbirth or with aging/menopause.
• Vaginal dryness, atrophy, or discomfort (e.g., painful intercourse/dyspareunia).
• Improved sexual function/sensation.
• In some practices, it’s promoted for reducing recurrent/chronic UTIs or recurrent yeast infections indirectly — by restoring vaginal tissue health, improving lubrication, pH balance, and mucosal integrity, which can lower infection risk over time (e.g., less irritation, better barrier function).

Votiva uses bipolar RF energy (via applicators like FormaV for internal vaginal canal treatment and sometimes FractoraV for external vulvar/labial areas). Treatments are typically 2–3 sessions, 20–40 minutes each, with minimal downtime and no anesthesia needed. Many patients report noticeable improvements in bladder control, comfort, and reduced recurrent infection episodes after completing the series.

Important Distinctions for UTI Management

• For an acute UTI: Votiva does not replace antibiotics. Standard care remains urine culture-guided antibiotics (e.g., nitrofurantoin, fosfomycin, TMP-SMX), hydration, and symptom management.
• For recurrent UTIs (especially in postmenopausal women or those with vaginal atrophy): Votiva (or similar RF/laser therapies like MonaLisa Touch) may serve as an adjunct/preventive option. Evidence shows improved vaginal epithelium and reduced infection frequency in some studies/case series, but it’s not first-line and results vary. Estrogen therapy (topical vaginal) remains a stronger evidence-based preventive strategy for atrophic-related recurrent UTIs.
• No major adverse events are commonly reported, but it’s contraindicated in active infection, certain skin conditions, or pacemakers (check full list).

If you’re asking about Votiva in the context of a patient with recurrent UTIs, postmenopausal symptoms, or incontinence — it’s a reasonable non-hormonal option to discuss, especially if estrogen is declined or contraindicated.

If this doesn’t match what you meant (e.g., a specific brand name tablet, misspelling of another drug, or something else), provide more context — happy to refine! As always, individual assessment and counseling are key.